S
Sara De Dosso
Researcher at University of Milan
Publications - 44
Citations - 5516
Sara De Dosso is an academic researcher from University of Milan. The author has contributed to research in topics: Colorectal cancer & Cetuximab. The author has an hindex of 17, co-authored 36 publications receiving 5162 citations.
Papers
More filters
Journal ArticleDOI
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock,Bart Claes,David Bernasconi,Jef De Schutter,Bart Biesmans,George Fountzilas,Konstantine T. Kalogeras,Vassiliki Kotoula,Demetris Papamichael,Pierre Laurent-Puig,Frédérique Penault-Llorca,Philippe Rougier,Bruno Vincenzi,Daniele Santini,Giuseppe Tonini,Federico Cappuzzo,Milo Frattini,Francesca Molinari,Piercarlo Saletti,Sara De Dosso,Miriam Martini,Alberto Bardelli,Salvatore Siena,Andrea Sartore-Bianchi,Josep Tabernero,Teresa Macarulla,Frédéric Di Fiore,Alice Gangloff,Fortunato Ciardiello,Per Pfeiffer,Camilla Qvortrup,Tine Plato Hansen,Eric Van Cutsem,Hubert Piessevaux,Diether Lambrechts,Mauro Delorenzi,Mauro Delorenzi,Sabine Tejpar +37 more
TL;DR: This is the largest cohort to date of patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab plus chemotherapy in the pre-KRAS selection era and confirmed that, if KRAS is not mutated, assessing BRAF, NRAS, and PIK3CA population response rates confirmed that.
Journal ArticleDOI
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio,Miriam Martini,Francesca Molinari,Andrea Sartore-Bianchi,Sabrina Arena,Piercarlo Saletti,Sara De Dosso,Luca Mazzucchelli,Milo Frattini,Salvatore Siena,Alberto Bardelli +10 more
TL;DR: BRAF wild-type is required for response to panitumumab or cetuximab and could be used to select patients who are eligible for the treatment and should be used for selection.
Journal ArticleDOI
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
Andrea Sartore-Bianchi,Miriam Martini,Francesca Molinari,Silvio Veronese,Michele Nichelatti,Salvatore Artale,Federica Di Nicolantonio,Piercarlo Saletti,Sara De Dosso,Luca Mazzucchelli,Milo Frattini,Salvatore Siena,Alberto Bardelli +12 more
TL;DR: The mutational analysis of PIK3CA and KRAS and evaluation of the PTEN protein status in a cohort of 110 patients with mCRC treated with anti-EGFR moAbs indicate that Pik3CA mutations can independently hamper the therapeutic response to panitumumab or cetuximab in mC RC.
Journal ArticleDOI
Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
Andrea Sartore-Bianchi,Federica Di Nicolantonio,Michele Nichelatti,Francesca Molinari,Sara De Dosso,Piercarlo Saletti,Miriam Martini,Tiziana Cipani,Giovanna Marrapese,Luca Mazzucchelli,Simona Lamba,Silvio Veronese,Milo Frattini,Alberto Bardelli,Salvatore Siena +14 more
TL;DR: When expression of PTEN and mutations of KRAS, BRAF and PIK3CA are concomitantly ascertained, up to 70% of mCRC patients unlikely to respond to anti-EGFR therapies can be identified.
Journal ArticleDOI
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
Emilio Bajetta,Laura Catena,Giuseppe Procopio,Sara De Dosso,Ettore Bichisao,Leonardo Ferrari,Antonia Martinetti,Marco Platania,Elena Verzoni,Barbara Formisano,Roberto Bajetta +10 more
TL;DR: The XELOX regimen is effective and tolerated in well-differentiated NETs after progression following somatostatin analogues and biochemical and symptomatic responses were 20 and 50%, respectively.